Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides).
Journal article published in 2018 by
M. Moreno 
,
J. Gratacós ,
V. Navarro Compán,
E. de Miguel,
P. Font,
T. Clavaguera,
Linares Lf,
L. F. Linares,
B. Joven,
X. Juanola,
and the Regisponserbio Group
,
J. Gratacós ,
V. Navarro Compán,
E. de Miguel,
P. Font,
T. Clavaguera,
Linares Lf,
L. F. Linares,
B. Joven,
X. Juanola,
and the Regisponserbio Group
